Cargando…

Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome

Background. Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-threatening disorder for which eculizumab is the only approved treatment. Life-long treatment is indicated; however, eculizumab discontinuation has been reported. Methods. Unpublished authors’ cases and published cases of eculiz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macia, Manuel, de Alvaro Moreno, Fernando, Dutt, Tina, Fehrman, Ingela, Hadaya, Karine, Gasteyger, Christoph, Heyne, Nils
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Hereditary Kidney Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466111/ https://www.ncbi.nlm.nih.gov/pubmed/28621343 http://dx.doi.org/10.1093/ckj/sfw115

Ejemplares similares

Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
por: Rodriguez, Eva, et al.
Publicado: (2017)

Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017)

Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome
por: Ryan, Michael, et al.
Publicado: (2019)

Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey
por: El-Damanawi, Ragada, et al.
Publicado: (2017)

Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes
por: Ariceta, Gema, et al.
Publicado: (2021)

Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012)

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis
por: Socié, Gérard, et al.
Publicado: (2019)

Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal
por: Duineveld, Caroline, et al.
Publicado: (2020)

Eculizumab and drug-induced haemolytic–uraemic syndrome
por: Faguer, Stanislas, et al.
Publicado: (2013)

Novel complement factor H gene mutation causing atypical haemolytic uraemic syndrome: early Eculizumab prevents acute dialysis
por: Collett, James, et al.
Publicado: (2017)

Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential
por: Dowen, Frances, et al.
Publicado: (2017)

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
por: Rathbone, John, et al.
Publicado: (2013)

Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome
por: Durán, Carlos E., et al.
Publicado: (2012)

Eculizumab in atypical haemolytic–uraemic syndrome allows cessation of plasma exchange and dialysis
por: Kim, Jon Jin, et al.
Publicado: (2012)

Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome
por: Walsh, Patrick R., et al.
Publicado: (2018)

Atypical Haemolytic Uraemic Syndrome Associated with Clostridium difficile Infection Successfully Treated with Eculizumab
por: Inglis, Joshua M., et al.
Publicado: (2018)

Progression to end-stage renal disease is reduced with eculizumab in patients with atypical haemolytic uraemic syndrome
por: Walle, J Vande, et al.
Publicado: (2015)

10. Is Eculizumab a life-saving treatment for atypical Haemolytic Uraemic Syndrome in Lupus Pregnancy?
por: McGrath, Catherine, et al.
Publicado: (2017)

Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection
por: Fraga-Rodriguez, Gloria M, et al.
Publicado: (2017)

Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective
por: ter Avest, Mendy, et al.
Publicado: (2022)

Eculizumab treatment of atypical haemolytic uraemic syndrome: results from the largest prospective clinical trial to date
por: weekers, LE, et al.
Publicado: (2014)

Early eculizumab use in atypical haemolytic uraemic syndrome in a Jehovah’s Witness refusing blood products
por: Al-Shaghana, May, et al.
Publicado: (2017)

Successful Subsequent Pregnancy in a Woman Receiving Eculizumab for Pregnancy-Associated Atypical Haemolytic Uraemic Syndrome
por: Bateman, Samantha, et al.
Publicado: (2019)

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice
por: Delmas, Yahsou, et al.
Publicado: (2013)

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice
por: Delmas, Yahsou, et al.
Publicado: (2013)

Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study
por: Menne, Jan, et al.
Publicado: (2018)

Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan
por: Ito, Shuichi, et al.
Publicado: (2022)

Successful treatment of a Streptococcus pneumoniae-associated haemolytic uraemic syndrome by eculizumab
por: Jeantet, Guillaume, et al.
Publicado: (2018)

Treatment of atypical uraemic syndrome in the era of eculizumab
por: Fremeaux-Bacchi, Veronique
Publicado: (2012)

Hereditary angioedema patients would prefer newer-generation oral prophylaxis
por: Geba, Daniela, et al.
Publicado: (2021)

Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
por: Syed, Yahiya Y.
Publicado: (2021)

Recent advances in diagnosis and treatment of atypical haemolytic uraemic syndrome
por: Bolton-Maggs, Paula HB
Publicado: (2010)

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
por: Wong, Edwin K.S., et al.
Publicado: (2013)

Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
por: Syed, Yahiya Y.
Publicado: (2021)

Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
por: Syed, Yahiya Y.
Publicado: (2021)

Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab
por: Delmas, Yahsou, et al.
Publicado: (2014)

Early initiation of eculizumab treatment in patients with atypical haemolytic uraemic syndrome improves long-term outcomes: a pooled analysis of clinical trials
por: Walle, J Vande, et al.
Publicado: (2015)

Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study
por: Dunn, Sarah, et al.
Publicado: (2022)

Atypical Haemolytic Uraemic Syndrome Associated with a Hybrid Complement Gene
por: Venables, Julian P, et al.
Publicado: (2006)

AZD-1222: Atypical haemolytic uraemic syndrome recurrence: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r7qu8l5r7ic7u5tv9p7escjt5v